3 Reasons to Buy AbbVie Stock for the Long Haul

According to Motley Fool, AbbVie (ABBV) presents a compelling investment opportunity for long-term investors. Here are three reasons supporting this view:

1. Strong and Diversified Product Portfolio

AbbVie boasts a wide range of successful drugs, most notably Humira for rheumatoid arthritis, which has been one of the world's best-selling drugs. Additionally, the company is developing new drugs in promising therapeutic areas such as oncology and immunology, ensuring future revenue streams.

2. Attractive Dividend Yield

AbbVie has a strong track record of dividend payments, offering a competitive yield to investors. The company has consistently increased its dividends, making it a favorite among income-focused investors.

3. Clear Growth Strategy

AbbVie focuses on growth through strategic acquisitions and R&D. For instance, its acquisition of Allergan strengthened its portfolio in aesthetics and eye care. The company also invests heavily in innovation, positioning itself well to face patent expiration challenges.

What This Means for Investors

While AbbVie faces risks such as the Humira patent cliff, its strong fundamentals and diversified strategy make it a reasonable choice for long-term investors. Always conduct your own research before making investment decisions.